In this episode, Ross Katz sits down with Fred Manby, Co-Founder and Chief Technology Officer of Iambic Therapeutics, to explore how cutting-edge AI technologies are reshaping the landscape of drug discovery. From building advanced machine learning platforms to designing user-friendly interfaces for scientists, Fred shares insights into the company’s approach to tackling some of the biggest challenges in biotech.
Fred dives into the unique capabilities of Iambic’s Enchant multi-modal transformer model, its differentiation from other biological foundation models, and the importance of aligning model architecture with data creation and acquisition in modern drug discovery. We also discuss Iambic’s data-driven approach to developing oncology drugs, the exciting possibilities of incorporating new modalities like imaging, and the recent breakthroughs in protein-ligand structure prediction with NeuralPLexer3.
Highlights:
- Enchant Multi-Modal Transformer Model: How it systematically surpasses state-of-the-art molecular AI technologies.
- Uncertainty Quantification: The role of probabilities and predictions in streamlining drug discovery.
Interface Design for Scientists: Iambic’s approach to integration between AI platforms and experimental workflows.
Connect with Our Guest:
- Sponsor: CorrDyn, a data consultancy
- Find out more about Iambic’s work on their website
Connect with Fred Manby on LinkedIn
